Targeted therapies directed against IL-5 and IL-5R for severe eosinophilic asthma have proved effective mainly in reducing asthma exacerbations and the use of daily oral corticosteroids but also in improving asthma control and lung function. The gene discussed is IL5RA; the disease is asthma.